<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00016367</url>
  </required_header>
  <id_info>
    <org_study_id>DM99-015</org_study_id>
    <secondary_id>P30CA016672</secondary_id>
    <secondary_id>MDA-DM-99015</secondary_id>
    <secondary_id>NCI-4450</secondary_id>
    <secondary_id>CDR0000068626</secondary_id>
    <nct_id>NCT00016367</nct_id>
  </id_info>
  <brief_title>Cisplatin and Gemcitabine Plus Trastuzumab in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer</brief_title>
  <official_title>Phase II Multidose, Single Arm, Multicenter Clinical Trial of Cisplatin and Gemcitabine in Combination With Recombinant Humanized Anti-p185HER2 Monoclonal Antibody (Herceptin) in Patients Who Have Untreated p185HER2 Overexpressing Advanced Local Stage (Stage IIIb Pleural Effusion Only) and Metastatic (Stage IV) Non-Small Cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so
      they stop growing or die. Monoclonal antibodies such as trastuzumab can locate tumor cells
      and either kill them or deliver tumor-killing substances to them without harming normal
      cells. Combining chemotherapy with monoclonal antibody therapy may kill more tumor cells.

      PURPOSE: Phase II trial to study effectiveness of combining cisplatin, gemcitabine, and
      trastuzumab in treating patients who have stage IIIB or stage IV non-small cell lung cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES: I. Determine the therapeutic efficacy and toxicity of cisplatin, gemcitabine, and
      trastuzumab (Herceptin) in patients with untreated p185-HER2 overexpressing stage IIIB or IV
      non-small cell lung cancer. II. Determine the pharmacokinetic interactions among these drugs
      in these patients. III. Assess the pharmacodynamics of these drugs in these patients.

      OUTLINE: This is a multicenter study. Regimen A: Patients receive gemcitabine IV over 30
      minutes followed by cisplatin IV over 2 hours on day 1 and trastuzumab (Herceptin) IV over 90
      minutes on day 2. Patients receive trastuzumab IV over 90 minutes followed by gemcitabine IV
      over 30 minutes on day 8 and trastuzumab IV over 90 minutes on day 15. Patients proceed to
      regimen B on day 22 of regimen A. Regimen B: Patients receive trastuzumab IV over 30-90
      minutes, gemcitabine IV over 30 minutes, and cisplatin IV over 2 hours on day 1. Patients
      receive trastuzumab IV over 30-90 minutes followed by gemcitabine IV over 30 minutes on day 8
      and trastuzumab IV over 30-90 minutes on day 15. Treatment repeats every 21 days for up to 5
      courses in the absence of disease progression or unacceptable toxicity. Maintenance: After
      completion of 6 courses, patients with stable disease or partial response receive trastuzumab
      IV over 30-90 minutes weekly until tumor progression.

      PROJECTED ACCRUAL: A total of 20-48 patients will be accrued for this study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2001</start_date>
  <completion_date type="Actual">December 2004</completion_date>
  <primary_completion_date type="Actual">December 2004</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy of Cisplatin, Gemcitabine, + Trastuzumab in Untreated p185-HER2 Overexpressing Stage IIIB or IV Non-small Cell Lung Cancer</measure>
    <time_frame>21 days cycles for 6 courses</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">22</enrollment>
  <condition>Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Regimen A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Gemcitabine IV followed by Cisplatin IV Day 1 and Trastuzumab (Herceptin) IV Day 2; Trastuzumab IV followed by Gemcitabine IV Day 8 and Trastuzumab IV Day 15.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Regimen B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Starting Day 22 of regimen A, Trastuzumab IV, Gemcitabine IV, and Cisplatin IV Day 1. Trastuzumab IV followed by Gemcitabine IV Day 8 and Trastuzumab IV Day 15. Repeats every 21 days for up to 5 courses.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Trastuzumab</intervention_name>
    <description>Regimen A: Trastuzumab IV over 90 minutes on days 2 and 8.
Regimen B: Trastuzumab IV over 30-90 minutes on days 1, 8 and 15.</description>
    <arm_group_label>Regimen A</arm_group_label>
    <arm_group_label>Regimen B</arm_group_label>
    <other_name>Herceptin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin</intervention_name>
    <description>Regimen A: Cisplatin IV over 2 hours on day 1 following gemcitabine.
Regimen B: Cisplatin IV over 2 hours on day 1.</description>
    <arm_group_label>Regimen A</arm_group_label>
    <arm_group_label>Regimen B</arm_group_label>
    <other_name>Platinol</other_name>
    <other_name>Platinol-AQ</other_name>
    <other_name>CDDP</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine Hydrochloride</intervention_name>
    <description>Regimen A: Gemcitabine IV over 30 minutes on day 1. Gemcitabine IV over 30 minutes on day 8 following Trastuzumab.
Regimen B: Gemcitabine IV over 30 minutes on day 1. Gemcitabine IV over 30 minutes on day 8 following Trastuzumab.</description>
    <arm_group_label>Regimen A</arm_group_label>
    <arm_group_label>Regimen B</arm_group_label>
    <other_name>Gemzar</other_name>
    <other_name>Gemcitabine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS: Immunohistochemically confirmed p185-HER2 expressing stage IIIB
        (pleural effusions only) or IV non-small cell lung cancer Confirmed overexpression at
        least: 1+ p185-HER2 (by DAKO Hercep Test) OR 15 ng/mL serum HER2/neu shed antigen (by Human
        HER2 Quantitative ELISA) At least 1 site of measurable disease outside of prior radiation
        port Brain metastases allowed provided clinical neurologic status is stable and head CT
        scan is stable to improved

        PATIENT CHARACTERISTICS: Age: Over 18 Performance status: Zubrod 0-2 Life expectancy: More
        than 12 weeks Hematopoietic: WBC at least 3,000/mm3 Absolute neutrophil count at least
        1,500/mm3 Platelet count at least 100,000/mm3 Hemoglobin at least 10 g/dL (transfusion
        allowed) Hepatic: Bilirubin less than 1.5 mg/dL SGPT no greater than 1.5 times normal
        Renal: Creatinine clearance at least 60 mL/min Cardiovascular: No myocardial infarction
        within the past 6 months No unstable angina, uncontrolled congestive heart failure, or
        uncontrolled arrhythmia Ejection fraction at least 40% Other: No other malignancy within
        the past 5 years No concurrent serious infection, including post-obstructive pneumonia No
        more than 10% weight loss in past 3 months Not pregnant or nursing Negative pregnancy test
        Fertile patients must use adequate contraception

        PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: No prior
        chemotherapy No other concurrent chemotherapy Endocrine therapy: Not specified
        Radiotherapy: See Disease Characteristics At least 3 weeks since prior radiotherapy
        (including radiotherapy for brain metastases) No concurrent radiotherapy to only site of
        measurable disease Surgery: At least 2 weeks since prior major surgery No concurrent
        surgery on only site of measurable disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Roy S. Herbst, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Texas - MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030-4009</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>UT MD Anderson Cancer Center Website</description>
  </link>
  <verification_date>July 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 6, 2001</study_first_submitted>
  <study_first_submitted_qc>February 26, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 27, 2004</study_first_posted>
  <last_update_submitted>July 27, 2012</last_update_submitted>
  <last_update_submitted_qc>July 27, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 30, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stage IIIB non-small cell lung cancer</keyword>
  <keyword>stage IV non-small cell lung cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Trastuzumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

